Rational Approaches to Treatment Duration with Immunotherapy in Metastatic Renal Cell Carcinoma

Nirmish Singla, Yuval Freifeld, Rashed A. Ghandour, Hans J. Hammers

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of kidney cancer. Given the sustained response to ICIs in some patients after treatment discontinuation, intermittent dosing may minimize treatment toxicities and costs. Determining an optimal treatment strategy relies on personalized approaches.

Original languageEnglish (US)
Pages (from-to)31-33
Number of pages3
JournalEuropean Urology Focus
Volume6
Issue number1
DOIs
StatePublished - Jan 15 2020

Keywords

  • Financial burden
  • Immune checkpoint inhibitors
  • Immune-related adverse events
  • Intermittent dosing
  • Metastatic renal cell carcinoma
  • Treatment duration

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Rational Approaches to Treatment Duration with Immunotherapy in Metastatic Renal Cell Carcinoma'. Together they form a unique fingerprint.

  • Cite this